PCSK9 Catalytic Domain Peptides for LDL Receptor Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cholesterol-lowering agents, such as statins, have limitations including side effects and not all patients respond effectively, leading to a need for alternative therapies that can safely and efficiently reduce LDL-cholesterol levels.
Innovation Solution
Development of small molecule PCSK9 inhibitors derived from the catalytic domain of the PCSK9 protein, specifically peptides that bind to the LDL receptor, to prevent its degradation and thereby increase its levels on the cell surface, thereby reducing cholesterol levels in the blood.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If statins are used to lower cholesterol, then cholesterol levels are reduced, but side effects occur and not all patients respond effectively
Solution Approach 1:
The patent extracts the catalytic domain (residues 153-421) from the full-length PCSK9 protein to create peptide inhibitors. This extraction focuses on the essential functional region that binds to LDL-R, creating a smaller, more targeted therapeutic agent that avoids some limitations of full-length protein while maintaining the ability to promote LDL-R activity and reduce cholesterol
Solution Approach 2:
The patent creates peptide copies of the PCSK9 catalytic domain that replicate its natural binding function to LDL-R. These peptide copies (such as those based on residues 365-384 containing the disulfide bridge) mimic the structure and function of the native protein domain, enabling them to bind LDL-R and prevent degradation without requiring the complete PCSK9 structure
2Reliability
If full-length PCSK9 is used to bind LDL-R, then LDL-R degradation is promoted, but the protein is too large and complex for effective drug development
Solution Approach 1:
The patent segments the PCSK9 protein into functional domains, specifically isolating the catalytic domain (residues 153-421) as the therapeutically active portion. Further segmentation identifies critical sub-regions such as residues 365-384 containing the disulfide bridge between Cys375 and Cys378, creating progressively smaller peptide fragments that retain LDL-R binding capability while reducing complexity
Solution Approach 2:
The patent applies local quality by concentrating the therapeutic activity in specific regions of the PCSK9 sequence. The disulfide bridge region (residues 365-384) is identified as particularly critical for maintaining the structural integrity and binding function. By focusing on this local region with enhanced structural stability, the patent creates peptides that are both simpler and more effective
Data Source
AI summary
The present invention provides compositions comprising an isolated or purified therapeutically effective hPCSK9 polypeptide derived from the hPCSK9 catalytic domain, and their use in methods of treating hypercholesterolemia.